Migraine Medication Effects on Urinary Symptoms

StatusEnrolling by Invitation
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 12 months later May 2026 → Jun 2027
See other at-risk trials from The Cleveland Clinic

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from May 2026 to Jun 2027
    • Study completion pushed from Dec 2026 to Dec 2027
    • Eligibility criteria expanded, about 16 words
    • Secondary endpoints: details revised at 2 of 2 entries
  2. Primary completion date: May 2025 to May 2026
    • Study completion date: May 2026 to Dec 2026
    v5
  3. Primary completion date: Mar 2025 to May 2025
    • Study completion date: Mar 2026 to May 2026
    • Start date changed from estimate of Mar 2024 to Apr 5, 2024
    v4
  4. Trial status: Not Yet Recruiting to Enrolling by Invitation
    • Site contact updated
    v3
  5. Start date: Jan 2024 to Mar 2024v2 Show 4 more changesShow less
    • Primary completion date: Jan 2025 to Mar 2025
    • Study completion date: Jan 2026 to Mar 2026
    • Secondary endpoints: details revised at 2 of 2 entries
    • Study description expanded, about 1 word
  6. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The Cleveland Clinic
212 trials monitored
See 34 trials at risk
Migraine
483 trials monitored
See 27 trials at risk
A prospective observational cohort trial to study the effects of CGRP inhibitors (CGRPi) on lower urinary tract symptoms (LUTS) and bladder/pelvic pain. Candidates for either CGRPi or an alternative therapy for refractory migraines (OnabotulinumtoxinA (BoNTA) extracranial muscle injections) with baseline LUTS will be recruited. The investigators will assess LUTS and pelvic pain using validated symptom and quality-of-life questionnaires, pretreatment and at 3 months post-treatment follow-up, comparing change in symptoms based on treatment received.
Trial Details
NCT Number NCT06212661
Lead Sponsor The Cleveland Clinic
Conditions
(from sponsor)		 Overactive Bladder, Bladder Pain Syndrome, Migraine Disorders, Overactive Bladder Syndrome, Overactive Detrusor, Migraine, Interstitial Cystitis
Related terms Cystitis, Interstitial, Migraine Disorders, Urinary Bladder, Overactive
Enrollment 200 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov